Redcare Pharmacy NV (RDC.DE)
EUR 139.9
(-3.38%)
EUR 139.9
(-3.38%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -16.73 Million EUR | 75.8% |
| 2022 | -69.17 Million EUR | -5.29% |
| 2021 | -65.69 Million EUR | -7486.37% |
| 2020 | -866 Thousand EUR | 97.41% |
| 2019 | -33.44 Million EUR | -16.41% |
| 2018 | -28.73 Million EUR | -49.66% |
| 2017 | -19.19 Million EUR | -64.94% |
| 2016 | -11.63 Million EUR | -31.98% |
| 2015 | -8.81 Million EUR | -117.86% |
| 2014 | -4.04 Million EUR | -115.55% |
| 2013 | -1.87 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -5.75 Million EUR | 75.65% |
| 2024 Q2 | -3.19 Million EUR | 44.53% |
| 2023 Q1 | -7.57 Million EUR | 34.04% |
| 2023 Q3 | -2.01 Million EUR | 9.59% |
| 2023 Q2 | -2.23 Million EUR | 70.55% |
| 2023 Q4 | -23.65 Million EUR | -1071.95% |
| 2023 FY | -16.73 Million EUR | 75.8% |
| 2022 Q3 | -16.7 Million EUR | 23.32% |
| 2022 Q4 | -11.49 Million EUR | 31.21% |
| 2022 FY | -69.17 Million EUR | -5.29% |
| 2022 Q1 | -19.19 Million EUR | 56.14% |
| 2022 Q2 | -21.78 Million EUR | -13.5% |
| 2021 Q1 | -2.42 Million EUR | -17.52% |
| 2021 Q2 | -7.62 Million EUR | -214.79% |
| 2021 Q3 | -11.89 Million EUR | -56.1% |
| 2021 FY | -65.69 Million EUR | -7486.37% |
| 2021 Q4 | -43.76 Million EUR | -267.85% |
| 2020 Q3 | -1.28 Million EUR | -165.23% |
| 2020 FY | -866 Thousand EUR | 97.41% |
| 2020 Q4 | -2.06 Million EUR | -60.06% |
| 2020 Q2 | 1.97 Million EUR | 288.39% |
| 2020 Q1 | 508 Thousand EUR | 106.27% |
| 2019 Q2 | -4.98 Million EUR | 62.53% |
| 2019 FY | -33.44 Million EUR | -16.41% |
| 2019 Q1 | -13.31 Million EUR | -43.43% |
| 2019 Q4 | -8.1 Million EUR | -15.29% |
| 2019 Q3 | -7.03 Million EUR | -40.97% |
| 2018 Q4 | -9.28 Million EUR | -54.56% |
| 2018 FY | -28.73 Million EUR | -49.66% |
| 2018 Q1 | -8.05 Million EUR | 2.1% |
| 2018 Q2 | -5.38 Million EUR | 33.18% |
| 2018 Q3 | -6 Million EUR | -11.55% |
| 2017 Q1 | -4.85 Million EUR | -7.48% |
| 2017 Q2 | -2.23 Million EUR | 53.91% |
| 2017 Q4 | -8.23 Million EUR | -112.5% |
| 2017 Q3 | -3.87 Million EUR | -73.06% |
| 2017 FY | -19.19 Million EUR | -64.94% |
| 2016 Q4 | -4.51 Million EUR | -104.34% |
| 2016 Q3 | -2.21 Million EUR | -14.56% |
| 2016 Q2 | -1.93 Million EUR | 35.23% |
| 2016 Q1 | -2.98 Million EUR | 9.15% |
| 2016 FY | -11.63 Million EUR | -31.98% |
| 2015 Q1 | -1.49 Million EUR | 0.0% |
| 2015 FY | -8.81 Million EUR | -117.86% |
| 2015 Q2 | -1.49 Million EUR | 0.0% |
| 2015 Q4 | -3.28 Million EUR | -37.01% |
| 2015 Q3 | -2.39 Million EUR | -59.76% |
| 2014 FY | -4.04 Million EUR | -115.55% |
| 2013 FY | -1.87 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Newron Pharmaceuticals S.p.A. | -11.62 Million EUR | -43.95% |